Tags : Treating

STADA Expands its Specialty Footprint with the Acquisition of Lobsor

Tuba Khan October 5, 2020

Shots: STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease With the acquisition, STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology, already launched in Nordic countries Levodopa, carbidopa and […]Read More

Biotech COVID-19

GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with

Tuba Khan May 8, 2020

Shots: GSK will initiate a clinical trial to evaluate its RA drug, otilimab on patients suffering from pneumonia related to COVID-19 at the end of May’2020. The study will evaluate the efficacy and safety of otilimab (IV) vs PBO in addition to SOC in ~800 patients with severe COVID-19 related pulmonary disease The company anticipates […]Read More

COVID-19 Pharma

I-Mab to Initiate the Development of TJM2 for Treating Cytokine

Tuba Khan March 13, 2020

The initiation of clinical study follows the US FDA’s acceptance of IND for TJM2 (TJ003234). The study will explore the potential of TJM2 and initially be conducted in the US and is expected to expand in other countries The company has successfully completed its P-I SAD study, which demonstrated favorable safety, tolerability, PK/PD, and immunogenicity […]Read More

Pharma

IMIDomics Collaborates with Gossamer Bio to Develop Therapies for Treating

Vartika Singh February 4, 2020

Shots: The companies collaborates on multiple projects, being the first for inflammatory bowel disease(IBD) to develop and discover therapies for treating Immune-Mediated Inflammatory Diseases (IMIDs) The focus of the collaboration will allow Gossamer’s immunology research and development team to utilize IMIDomics’ unique clinical and molecular patient database for product discovery and development strategy IMIDomics’ platform […]Read More

Pharma

BeiGene Signs an Exclusive Worldwide License Agreement with Seattle Genetics

Vartika Singh November 6, 2019

Shots: Seattle to receive upfront plus progress-dependent milestones of up to $160M and royalties on any product sales, retaining rights for candidates in Americas (the US, Canada, and Latin American countries), EU and Japan. BeiGene to get exclusive rights to develop and commercialize the candidates in Asia (Ex- Japan) and ROW and will also be […]Read More

Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens

MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Henlius’ HLX15 (biosimilar, daratumumab) Receives IND Approval for Multiple Myeloma in China

Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening

Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

AbbVie’s Rinvoq (upadacitinib) Receives the EC’s Approval for Psoriatic Arthritis and Ankylosing Spondylitis

Merck’s Keytruda (pembrolizumab) Receives EC’s Approval as 1L Treatment for Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer

Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

Tags : Treating

STADA Expands its Specialty Footprint with the Acquisition of Lobsor

GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with

I-Mab to Initiate the Development of TJM2 for Treating Cytokine

IMIDomics Collaborates with Gossamer Bio to Develop Therapies for Treating

BeiGene Signs an Exclusive Worldwide License Agreement with Seattle Genetics

Latest Posts

Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening

AbbVie’s Rinvoq (upadacitinib) Receives the EC’s Approval for Psoriatic Arthritis and Ankylosing Spondylitis

Regeneron Reports Results of REGEN-COV Antibody Cocktail Used as Passive Vaccine to Prevent COVID-19

Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

Tags : Treating

Latest Posts

Categories

Related Topics